GlassScriptPhysician profile
Vanna Kham
NPI 1548545718
$1,982.61
in general payments reported to CMS, 2019-2025
10 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,259 · 2022: $66.07 · 2023: $284 · 2024: $236 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $617.76 | 2021-2023 | |
| Viiv Healthcare Company | $376.93 | 2021 | |
| Janssen Biotech, INC. | $213.22 | 2021-2022 | |
| Gilead Sciences, INC. | $202.09 | 2021 | |
| Pfizer INC. | $164.96 | 2022-2024 | |
| Lundbeck LLC | $146.73 | 2024-2025 | Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $131.78 | 2024-2025 | Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $64.98 | 2023-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.92 | 2023 | |
| Janssen Pharmaceuticals, INC | $23.24 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanna Kham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.